Developer docs
API playgroundTry for free, no card

Search company profiles

Boundless Bio

Full company profile

uuid0000myf

Namestring
Boundless Bio
Legal namestring
Boundless Bio, Inc.
Company typeenum
Public
Founded yearint
2019
Descriptiontext

Boundless Bio is a clinical-stage precision oncology company developing ecDNA-directed therapies (ecDTx) for patients with oncogene amplified cancers. The company targets cancers characterized by extrachromosomal DNA (ecDNA), which is found in over 17% of solid tumors and underlies more than 25% of all cancers with oncogene amplifications — a population of more than 5 million newly diagnosed patients annually worldwide. Its core platform, Spyglass, is a proprietary drug discovery engine that combines cancer model systems, molecular analytical technologies, and data science to identify essential, druggable vulnerabilities unique to ecDNA-bearing cancer cells. ECHO, a proprietary software algorithm that detects ecDNA from routine clinical NGS data, is the first ecDNA diagnostic used in clinical trials for patient selection.

Boundless Bio's pipeline comprises three therapeutic programs targeting distinct ecDNA vulnerabilities: BBI-940, an oral kinesin degrader in Phase 1 development (KOMODO-1 trial) for ER+/HER2- breast cancer and TNBC-LAR subtypes, with preclinical single-agent tumor regressions; BBI-355, a CHK1 inhibitor targeting replication stress in oncogene amplified cancers; and RNR inhibitors designed to address ecDNA-mediated acquired resistance to KRAS inhibitors. The company is headquartered in San Diego, California, with scientific founders at Stanford, UCSD, and Scripps Research Institute, and trades on Nasdaq under ticker BOLD. In June 2026, Boundless Bio announced a definitive all-stock merger with privately held Serapha Bio, with the combined company to operate as Serapha Bio on Nasdaq under ticker AATD, focusing on gene editing therapy SERP-01 for alpha-1 antitrypsin deficiency.

As a pre-revenue clinical-stage biotechnology company, Boundless Bio's business model relies on equity financing to advance its pipeline through regulatory milestones, with future revenue contingent upon pharmaceutical product commercialization following regulatory approval. The company has raised approximately $251 million in cumulative equity financing (including a $100M Series C in May 2023) and a concurrent $230M PIPE financing tied to the Serapha merger, with Q1 2026 cash of $92.8M and a quarterly net loss of $13.6M. Go-to-market will be executed through traditional pharmaceutical commercialization pathways targeting oncologists and cancer treatment centers upon approval.

Short descriptiontext

Boundless Bio is a clinical-stage precision oncology company developing ecDNA-directed therapies (ecDTx) for patients with oncogene amplified cancers, using its proprietary Spyglass platform and ECHO diagnostic to advance a pipeline including BBI-940 and BBI-355.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision oncology therapeutics, ecDNA-directed therapies, oncogene amplified cancers, cancer drug discovery, targeted cancer therapies
Industry2 codes
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Precision Oncology Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Therapeutic Development and Commercialization
TypeOne Time License
Description

Pre-revenue clinical stage biotechnology company developing a pipeline of ecDNA-directed therapies for oncogene amplified cancers. Revenue will be generated through pharmaceutical product sales upon regulatory approval.

endpts.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Boundless Bio develops ecDNA-directed therapies (ecDTx), a class of precision oncology therapeutics that exploit vulnerabilities specific to cancers driven by extrachromosomal DNA (ecDNA). Its pipeline includes BBI-940, an oral kinesin degrader currently in the Phase 1 KOMODO-1 trial for ER+/HER2- breast cancer and TNBC-LAR subtypes, as well as BBI-355 (a CHK1 inhibitor) and RNR inhibitor programs. Drug discovery is enabled by the proprietary Spyglass platform, and the proprietary ECHO diagnostic algorithm supports patient selection in clinical trials.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Over 17% of patients with solid tumor have ecDNA in their cancer cells
+3 more records
Product overview1 text field

Boundless Bio is a clinical-stage precision oncology company developing a pipeline of ecDNA-directed therapies (ecDTx) targeting oncogene amplified cancers. The company's core offerings include three therapeutic programs built on its proprietary Spyglass discovery platform: BBI-940 (lead kinesin degrader in Phase 1), BBI-355 (CHK1 inhibitor), and additional RNR inhibitor programs. The company also offers ECHO, a proprietary diagnostic algorithm that identifies ecDNA-bearing tumors using clinical NGS data to enable precision patient selection for its therapies.

Product and service3 records
1BBI-940
CategoryPrecision Oncology Drug Candidate
Description

Novel, oral, potent, and selective degrader of kinesin that targets ecDNA segregation in cancer cells; demonstrates robust anti-tumor activity and single-agent tumor regressions in preclinical cancer cell line and xenograft models. Currently in Phase 1 KOMODO-1 trial for ER+/HER2- breast cancer and TNBC-LAR subtypes.

2BBI-355
CategoryPrecision Oncology Drug Candidate
Description

Checkpoint kinase 1 (CHK1) inhibitor targeting cancer cells with elevated replication stress due to high copy number gene amplifications on ecDNA. Developed as part of Boundless Bio's Replication Stress therapeutic approach for oncogene amplified cancers.

3ecDNA-directed therapies (ecDTx)
CategoryPrecision Oncology Therapeutic Pipeline
Description

Pipeline of next-generation precision oncology therapies designed to target and exploit vulnerabilities specific to oncogene amplified cancers driven by extrachromosomal DNA (ecDNA), covering three distinct therapeutic angles: DNA Segregation, Replication Stress, and DNA Assembly and Repair.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-06-24
Description

Boundless Bio and Serapha Bio entered into a definitive all-stock merger agreement in 2026. Boundless Bio shareholders expected to own approximately 3.7% of the combined company. Combined entity to operate under Serapha Bio name and trade on Nasdaq under ticker AATD, focusing on gene editing therapies.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Scientific co-founder Paul Mischel serves as Institute Scholar at Stanford University (ChEM-H) and Vice Chair of Research and Professor in the Dept of Pathology. Long-standing research collaboration in ecDNA biology.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Scientific co-founder Vineet Bafna is Professor of Computer Science & Engineering at UCSD. Company has deep ties to San Diego research ecosystem.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Scientific co-founder Ben Cravatt is Professor and Gilula Chair of Chemical Biology at The Scripps Research Institute. Academic collaboration in chemical biology and drug discovery.

Strategic tierMajorTypeTechnology or Integration
Description

Serapha Bio entered a licensing agreement with Shanghai-based YolTech Therapeutics for worldwide rights to SERP-01 (in vivo base editing therapy) outside Greater China, in exchange for undisclosed upfront payment and minority equity stake. This is part of the merged entity's pipeline.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage precision oncology company developing small molecule therapies against oncogenic drivers; comparable to Boundless Bio in stage, public-market profile, and focus on genomically-defined cancer populations.

TypeDirect peer
Description

Precision oncology company leveraging synthetic lethality and genome-wide CRISPR screens to develop targeted cancer therapies; highly comparable mechanism-discovery approach to Boundless Bio's Spyglass platform and clinical-stage profile.

TypeDirect peer
Description

Clinical-stage precision oncology company using motion-based drug design against oncogenic targets; similar stage, public-market status, and precision-oncology positioning to Boundless Bio.

TypeDirect peer
Description

Precision oncology company developing therapies targeting the RAS/MAPK pathway in oncogene-driven cancers; directly comparable in patient population (oncogene-amplified/activated tumors) and clinical stage.

5Nuvalent
TypeDirect peer
Description

Clinical-stage precision oncology company designing kinase inhibitors for genomically-defined cancers; comparable in oncology indication focus, public-market profile, and target-discovery approach.

TypeDirect peer
Description

Precision oncology biotech developing synthetic lethality and targeted therapies for biomarker-selected patient populations; closely matches Boundless Bio's precision-medicine model and clinical-stage profile.

TypeDirect peer
Description

Clinical-stage synthetic lethality-focused precision oncology company leveraging CRISPR-based target discovery; highly comparable to Boundless Bio's platform-driven approach and patient-selection strategy.

TypeDirect peer
Description

Clinical-stage oncology biotech developing medicines targeting chromatin biology and dysregulated gene expression; comparable in platform-driven precision oncology approach and clinical-stage status.

TypeEmerging player
Description

Clinical-stage precision medicine company developing targeted therapies; provides a comparable model of a San Diego-based precision therapeutics biotech with similar public-company growth trajectory.

10Ignyta
TypeOthers
Description

Acquired precision oncology company whose lead asset Rozlytrek was developed by Boundless CEO Zachary Hornby as COO before Ignyta's $2B sale to Roche; relevant as a comparable successful exit and as a talent pedigree benchmark.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors18 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Boundless Bio

Precision Oncology Therapeuticsboundlessbio.com

Boundless Bio is a clinical-stage precision oncology company developing ecDNA-directed therapies (ecDTx) for patients with oncogene amplified cancers, using its proprietary Spyglass platform and ECHO diagnostic to advance a pipeline including BBI-940 and BBI-355.

What Boundless Bio does

Boundless Bio is a clinical-stage precision oncology company developing ecDNA-directed therapies (ecDTx) for patients with oncogene amplified cancers. The company targets cancers characterized by extrachromosomal DNA (ecDNA), which is found in over 17% of solid tumors and underlies more than 25% of all cancers with oncogene amplifications — a population of more than 5 million newly diagnosed patients annually worldwide. Its core platform, Spyglass, is a proprietary drug discovery engine that combines cancer model systems, molecular analytical technologies, and data science to identify essential, druggable vulnerabilities unique to ecDNA-bearing cancer cells. ECHO, a proprietary software algorithm that detects ecDNA from routine clinical NGS data, is the first ecDNA diagnostic used in clinical trials for patient selection.

Boundless Bio's pipeline comprises three therapeutic programs targeting distinct ecDNA vulnerabilities: BBI-940, an oral kinesin degrader in Phase 1 development (KOMODO-1 trial) for ER+/HER2- breast cancer and TNBC-LAR subtypes, with preclinical single-agent tumor regressions; BBI-355, a CHK1 inhibitor targeting replication stress in oncogene amplified cancers; and RNR inhibitors designed to address ecDNA-mediated acquired resistance to KRAS inhibitors. The company is headquartered in San Diego, California, with scientific founders at Stanford, UCSD, and Scripps Research Institute, and trades on Nasdaq under ticker BOLD. In June 2026, Boundless Bio announced a definitive all-stock merger with privately held Serapha Bio, with the combined company to operate as Serapha Bio on Nasdaq under ticker AATD, focusing on gene editing therapy SERP-01 for alpha-1 antitrypsin deficiency.

As a pre-revenue clinical-stage biotechnology company, Boundless Bio's business model relies on equity financing to advance its pipeline through regulatory milestones, with future revenue contingent upon pharmaceutical product commercialization following regulatory approval. The company has raised approximately $251 million in cumulative equity financing (including a $100M Series C in May 2023) and a concurrent $230M PIPE financing tied to the Serapha merger, with Q1 2026 cash of $92.8M and a quarterly net loss of $13.6M. Go-to-market will be executed through traditional pharmaceutical commercialization pathways targeting oncologists and cancer treatment centers upon approval.

Boundless Bio firmographics

Firmographics
Name
Boundless Bio
Legal name
Boundless Bio, Inc.
Website
https://boundlessbio.com
Company type
Public
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Boundless Bio is a clinical-stage precision oncology company developing ecDNA-directed therapies (ecDTx) for patients with oncogene amplified cancers, using its proprietary Spyglass platform and ECHO diagnostic to advance a pipeline including BBI-940 and BBI-355.
Ownership category
akta.pro rank

Boundless Bio industry classification

Industry
Product category
Precision Oncology Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)

Keywords

  • Precision oncology therapeutics
  • EcDNA-directed therapies
  • Oncogene amplified cancers
  • Cancer drug discovery
  • Targeted cancer therapies

Where Boundless Bio is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Boundless Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. Therapeutic Development and Commercialization: Pre-revenue clinical stage biotechnology company developing a pipeline of ecDNA-directed therapies for oncogene amplified cancers. Revenue will be generated through pharmaceutical product sales upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Boundless Bio product offering

Product offering

Core offering

Boundless Bio develops ecDNA-directed therapies (ecDTx), a class of precision oncology therapeutics that exploit vulnerabilities specific to cancers driven by extrachromosomal DNA (ecDNA). Its pipeline includes BBI-940, an oral kinesin degrader currently in the Phase 1 KOMODO-1 trial for ER+/HER2- breast cancer and TNBC-LAR subtypes, as well as BBI-355 (a CHK1 inhibitor) and RNR inhibitor programs. Drug discovery is enabled by the proprietary Spyglass platform, and the proprietary ECHO diagnostic algorithm supports patient selection in clinical trials.

Product overview

Boundless Bio is a clinical-stage precision oncology company developing a pipeline of ecDNA-directed therapies (ecDTx) targeting oncogene amplified cancers. The company's core offerings include three therapeutic programs built on its proprietary Spyglass discovery platform: BBI-940 (lead kinesin degrader in Phase 1), BBI-355 (CHK1 inhibitor), and additional RNR inhibitor programs. The company also offers ECHO, a proprietary diagnostic algorithm that identifies ecDNA-bearing tumors using clinical NGS data to enable precision patient selection for its therapies.

Differentiator

Problem solved

Functional benefit

Products and services

  • BBI-940 Novel, oral, potent, and selective degrader of kinesin that targets ecDNA segregation in cancer cells; demonstrates robust anti-tumor activity and single-agent tumor regressions in preclinical cancer cell line and xenograft models. Currently in Phase 1 KOMODO-1 trial for ER+/HER2- breast cancer and TNBC-LAR subtypes.
  • BBI-355 Checkpoint kinase 1 (CHK1) inhibitor targeting cancer cells with elevated replication stress due to high copy number gene amplifications on ecDNA. Developed as part of Boundless Bio's Replication Stress therapeutic approach for oncogene amplified cancers.
  • ecDNA-directed therapies (ecDTx) Pipeline of next-generation precision oncology therapies designed to target and exploit vulnerabilities specific to oncogene amplified cancers driven by extrachromosomal DNA (ecDNA), covering three distinct therapeutic angles: DNA Segregation, Replication Stress, and DNA Assembly and Repair.

Quantifiable outcome

  • Over 17% of patients with solid tumor have ecDNA in their cancer cells
  • +3 more outcomes

Companies that use Boundless Bio

Customer profile

Segments2 records

Ideal customer profiles1 record

Boundless Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Boundless Bio partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered major and core.

  • Serapha BiomajorStrategic or Co-development Partner · 24 June 2026Boundless Bio and Serapha Bio entered into a definitive all-stock merger agreement in 2026. Boundless Bio shareholders expected to own approximately 3.7% of the combined company. Combined entity to operate under Serapha Bio name and trade on Nasdaq under ticker AATD, focusing on gene editing therapies.
  • Stanford UniversitycoreStrategic or Co-development PartnerScientific co-founder Paul Mischel serves as Institute Scholar at Stanford University (ChEM-H) and Vice Chair of Research and Professor in the Dept of Pathology. Long-standing research collaboration in ecDNA biology.
  • UC San DiegocoreStrategic or Co-development PartnerScientific co-founder Vineet Bafna is Professor of Computer Science & Engineering at UCSD. Company has deep ties to San Diego research ecosystem.
  • The Scripps Research InstitutecoreStrategic or Co-development PartnerScientific co-founder Ben Cravatt is Professor and Gilula Chair of Chemical Biology at The Scripps Research Institute. Academic collaboration in chemical biology and drug discovery.
  • YolTech TherapeuticsmajorTechnology or IntegrationSerapha Bio entered a licensing agreement with Shanghai-based YolTech Therapeutics for worldwide rights to SERP-01 (in vivo base editing therapy) outside Greater China, in exchange for undisclosed upfront payment and minority equity stake. This is part of the merged entity's pipeline.

Scale indicators8 records

Recent moves9 records

Expansion highlights6 records

Boundless Bio competitors and assessment

Company assessment

Direct peers

  • Black Diamond Therapeutics: Clinical-stage precision oncology company developing small molecule therapies against oncogenic drivers; comparable to Boundless Bio in stage, public-market profile, and focus on genomically-defined cancer populations.
  • Repare Therapeutics: Precision oncology company leveraging synthetic lethality and genome-wide CRISPR screens to develop targeted cancer therapies; highly comparable mechanism-discovery approach to Boundless Bio's Spyglass platform and clinical-stage profile.
  • Relay Therapeutics: Clinical-stage precision oncology company using motion-based drug design against oncogenic targets; similar stage, public-market status, and precision-oncology positioning to Boundless Bio.
  • Erasca: Precision oncology company developing therapies targeting the RAS/MAPK pathway in oncogene-driven cancers; directly comparable in patient population (oncogene-amplified/activated tumors) and clinical stage.
  • Nuvalent: Clinical-stage precision oncology company designing kinase inhibitors for genomically-defined cancers; comparable in oncology indication focus, public-market profile, and target-discovery approach.
  • IDEAYA Biosciences: Precision oncology biotech developing synthetic lethality and targeted therapies for biomarker-selected patient populations; closely matches Boundless Bio's precision-medicine model and clinical-stage profile.
  • Tango Therapeutics: Clinical-stage synthetic lethality-focused precision oncology company leveraging CRISPR-based target discovery; highly comparable to Boundless Bio's platform-driven approach and patient-selection strategy.
  • Foghorn Therapeutics: Clinical-stage oncology biotech developing medicines targeting chromatin biology and dysregulated gene expression; comparable in platform-driven precision oncology approach and clinical-stage status.

Emerging players

  • Crinetics Pharmaceuticals: Clinical-stage precision medicine company developing targeted therapies; provides a comparable model of a San Diego-based precision therapeutics biotech with similar public-company growth trajectory.

Others

  • Ignyta: Acquired precision oncology company whose lead asset Rozlytrek was developed by Boundless CEO Zachary Hornby as COO before Ignyta's $2B sale to Roche; relevant as a comparable successful exit and as a talent pedigree benchmark.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

Boundless Bio social profiles

Digital presence

Boundless Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Boundless Bio leadership team

Management profile

Number of profiles

Profiles9 records

Boundless Bio funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Boundless Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Boundless Bio

What does Boundless Bio do?

Boundless Bio develops ecDNA-directed therapies (ecDTx), a class of precision oncology therapeutics that exploit vulnerabilities specific to cancers driven by extrachromosomal DNA (ecDNA). Its pipeline includes BBI-940, an oral kinesin degrader currently in the Phase 1 KOMODO-1 trial for ER+/HER2- breast cancer and TNBC-LAR subtypes, as well as BBI-355 (a CHK1 inhibitor) and RNR inhibitor programs. Drug discovery is enabled by the proprietary Spyglass platform, and the proprietary ECHO diagnostic algorithm supports patient selection in clinical trials.

Is Boundless Bio a public or private company?

Boundless Bio is a public company. It is classified as public and is currently operating.

When was Boundless Bio founded?

Boundless Bio was founded in 2019. It employs 11 to 50 people.

Where is Boundless Bio based?

Boundless Bio is headquartered in San Diego, United States, in the North America region.

How does Boundless Bio make money?

One revenue line is on record: therapeutic Development and Commercialization.

Who are Boundless Bio's main competitors?

Direct peers on record are Black Diamond Therapeutics, Repare Therapeutics, Relay Therapeutics, Erasca, Nuvalent, IDEAYA Biosciences, Tango Therapeutics and Foghorn Therapeutics. Crinetics Pharmaceuticals is listed as an emerging player. Ignyta is listed as an others.

Does Boundless Bio have an API?

No public API is recorded for Boundless Bio.

What industry is Boundless Bio in?

Boundless Bio's product category is Precision Oncology Therapeutics. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation), with a secondary code of HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BostonGlobe.comBeam Therapeutics sues Chinese biotech, VC-backed startup, alleging theft of intellectual propertyBeam Therapeutics sued former scientist Zi Jun Wang and Chinese company YolTech Therapeutics, alleging Wang stole intellectual property to found YolTech, which co-founded Serapha Bio with VC firms. The lawsuit centers on Beam's base-editing treatment for AATD, with YolTech contesting the claims.Investing.comBoundless Bio director Kevin Tang buys $11,865 in shares By Investing.comKevin Tang, a director and 10% owner of Boundless Bio, Inc., purchased 4,863 shares of the company for $11,865 over three days in July 2026 at $2.44 per share, increasing his indirect beneficial ownership to 2,858,935 shares. The transactions occurred as BOLD shares have surged over 108% in the past year, trading at $2.48. Boundless Bio has separately announced a definitive merger agreement with privately held Serapha Bio, an all-stock transaction expected to close with Boundless Bio pre-merger stockholders receiving a cash dividend of $44 to $48 million.Investing.comThursday’s insider activity: Major sells dominate trading By Investing.comInsider trading activity reported on July 16, 2026 across U.S. public markets showed selling activity dominating, with Celcuity Inc. recording the largest insider sale at approximately $317.75 million by Baker Bros. Advisors LP, followed by Arista Networks at $54.2 million by shareholder Andreas Bechtolsheim. On the buying side, notable insider purchases included Boundless Bio shares purchased by ten percent owner Kevin Tang for $155,645, and Fidelity National Information Services Independent Chairman Jeffrey Goldstein acquiring $57,366 in shares.Investing.comBoundless Bio: ten percent owner Kevin Tang buys $155,645 By Investing.comKevin Tang, a ten percent owner of Boundless Bio, along with Tang Capital Management LLC, purchased 63,969 shares of the company's common stock totaling $155,645 over three consecutive days from July 14 to July 16, 2026, at prices ranging from $2.43 to $2.44 per share. The transactions were disclosed in a regulatory filing, with Tang now beneficially owning approximately 2,854,072 shares of Boundless Bio. The insider buying comes as Boundless Bio shares have surged over 111% in the past year, with the company also recently announcing a definitive merger agreement with Serapha Bio.Investing.comRTW Biotech Opportunities reports 9.7% June NAV increase By Investing.comRTW Biotech Opportunities Ltd reported its net asset value per ordinary share reached $2.86 as of June 30, representing a 9.7% increase from the previous month, matching the Nasdaq Biotech Index's return but trailing the Russell 2000 Biotech Index's 15.8% advance. The company invested $1.4 million in Lycia Therapeutics as part of a $75 million Series D financing round and $7.5 million in Serapha Bio's Series A financing, with an additional $7.5 million planned pending Serapha Bio's merger with Boundless Bio. Over the twelve months ending June 30, RTW Bio repurchased 7.6 million shares for $14.4 million, with the discount to NAV narrowing from 28.8% to 15.4%.Investing.comTang capital management, Kevin Tang buy $222k Boundless Bio stock By Investing.comTang Capital Management LLC and its sole manager Kevin Tang purchased $222,069 worth of Boundless Bio common stock between July 9 and July 13, 2026, acquiring a total of 91,585 shares at weighted-average prices ranging from $2.42 to $2.48 per share. Following these transactions, Tang entities hold approximately 2,790,103 shares of Boundless Bio, which recently announced a definitive merger agreement with Serapha Bio and plans to pay a cash dividend of approximately $44 to $48 million to pre-merger stockholders.Quiver QuantitativeInsider Stock Purchases: July 09, 2026 | Quiver QuantitativeOn July 9, 2026, Quiver Quantitative reported 163 open market insider transactions across multiple companies, highlighting several large stock purchases. Notable trades included Globalharvest Holdings Venture Ltd acquiring 650,415 shares of Mission Produce, Inc. for approximately $8.28 million and CEO Hakan Wohlin purchasing 300,000 shares of Viking Acquisition Corp. II for $3 million. The report also included historical insider trading data for Mission Produce, Evommune, Inc., and Boundless Bio, Inc. over the past six months.Investing.comBoundless Bio ten percent owner Kristina Burow sells $39,840 in stock By Investing.comKristina Burow, a ten percent owner of Boundless Bio, sold shares worth $39,840 on July 1, 2026 as part of a cashless stock option exercise, acquiring and disposing of 16,000 shares at $1.03 and $2.49 per share respectively. The net proceeds from this transaction were remitted to ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., and ARCH Venture Fund X, L.P., with the filing listing multiple ARCH-associated individuals as reporting owners. The article also notes Boundless Bio's pending all-stock merger with Serapha Bio, director elections, and recent corporate developments.Investing.comArch venture funds sell $39,840 in Boundless Bio stock By Investing.comSeveral ARCH Venture Funds, identified as ten-percent owners of Boundless Bio, Inc., reported the sale of 16,000 shares of Boundless Bio common stock totaling $39,840 on July 1, 2026. The transaction resulted from a cashless exercise of fully vested stock options, with shares acquired at $1.03 per share and immediately sold at $2.49 per share. Following the transaction, the three ARCH Venture Fund entities collectively hold approximately 2.69 million shares of Boundless Bio.FinancialContent Business PageHalper Sadeh LLC is Investigating Whether DAN, ESI, NUVL, BOLD are Obtaining Fair Deals for their ShareholdersHalper Sadeh LLC, an investor rights law firm, announced investigations into four proposed corporate transactions for potential violations of federal securities laws and breaches of fiduciary duties to shareholders. The transactions include Dana Incorporated's sale to Eaton Corporation plc, Element Solutions Inc's sale to Solstice Advanced Materials Inc for $10.00 cash plus 0.500 shares per share, Nuvalent Inc's sale to GSK plc for $124.00 per share, and Boundless Bio Inc's merger with Serapha Bio Inc. The law firm is inviting shareholders of these companies to discuss their legal rights and options at no cost.